-33%

Hexarelin 5 mg

Original price was: 29,99 €.Current price is: 19,99 €. with VAT

According to pharmacokinetic studies, hexarelin is one of the most potent GH secretagogues in the GHRP class. It is also unique in research due to a second mechanism of action—its binding to the CD36 receptor in cardiomyocytes, which is the subject of cardioprotective research independent of growth hormone.

Purity ≥ 98% – Each batch verified by HPLC; COA available upon request
5 mg of lyophilized powder, −20 °C | after reconstitution, store at 2–8 °C for up to 28 days
Shipped within 48 hours

In stock

Dosage calculator

Quantity discount

Quantity	Price	% Discount
7+	17,99 €	10%
4+	18,99 €	5%

Category: Research on muscle growth

All products are sold exclusively for the purpose of scientific research and development.
The chemical substances may not be used as a medicine, drug, active substance, medical device, cosmetic product, substance for the manufacture of a cosmetic product, or as a substance for human consumption, i.e. as a food or nutritional supplement, or in any other similar way on humans or animals.

All customers MUST be at least 18 years of age to purchase our products.

Laboratory-tested

Fast and Discreet Shipping

Purity Guarantee

98%+

Description

Hexarelin 5 mg – The Most Potent GHRP Secretagogue for GH Research and Cardioprotection

⚠️ Warning: This product is intended solely for scientific research purposes (research use only). It is not intended for use as a medicine, drug, dietary supplement, or for human use. Sale restricted to individuals over the age of 18.

What is Hexarelin?

Hexarelin is a synthetic hexapeptide (6 amino acids) belonging to the class of GH secretagogues (GHRP – Growth Hormone-Releasing Peptides). Within this class of compounds, hexarelin is considered one of the most potent GH secretagogues based on the results of preclinical and clinical pharmacokinetic studies.
Chemically, it is a modified hexapeptide with the following sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂, which contains D-amino acids that increase its metabolic stability against enzymatic degradation.

Synthetic hexapeptide: structure and classification within the GHRP class

GHRP (Growth Hormone-Releasing Peptides) are a group of synthetic peptides that stimulate the release of GH by acting on the ghrelin receptor (GHS-R1a). In addition to Hexarelin, this class includes GHRP-2, GHRP-6, and Ipamorelin, each of which exhibits a distinct pharmacological profile and potency.

Mechanism of action: GHS-R1a and GH secretion

The primary mechanism of action of Hexarelin is its agonism at the GHS-R1a (Growth Hormone Secretagogue Receptor 1a) —a receptor that is identical to the ghrelin receptor. Activation of this receptor on somatotrophic cells of the pituitary gland leads to the release of endogenous growth hormone (GH).
The mechanism involves activation of the phosphoinositide signaling pathway (PKC), which leads to an increase in intracellular Ca²⁺ and subsequent exocytosis of secretory granules containing GH.

Potency Compared to Other GHRP’s

Based on preclinical studies, Hexarelin exhibits significantly higher GH-stimulating activity compared to other members of the GHRP class:

GHRP compound	Relative Potency (GH Secretion)	Effect on cortisol/prolactin
Hexarelin	★★★★★ (highest)	Yes – increased cortisol and prolactin
GHRP-2	★★★★☆	Mild effect
GHRP-6	★★★☆☆	Mild effect, strong effect on ghrelin
Ipamorelin	★★★☆☆	High selectivity – minimal impact

Note: The table is based on preclinical pharmacokinetic data. The relative potency is approximate.

Unique Feature: Cardioprotective research independent of GH

The most significant and scientifically innovative aspect of Hexarelin is its cardioprotective mechanism, which has been documented in preclinical studies as being independent of GH secretion.

Binding to the CD36 receptor in cardiomyocytes

In addition to GHS-R1a, hexarelin binds to CD36 —a scavenger receptor expressed on the surface of cardiomyocytes, macrophages, and other cells—and to a truncated form of the GHS-R receptor present in cardiac tissue. This binding mediates direct cardioprotective effects independent of pituitary GH secretion.

Preclinical Studies: Ischemia, Reperfusion, and Apoptosis of Cardiomyocytes

In preclinical studies using isolated hearts (Langendorff model) and animal models, Hexarelin was investigated in the context of:

Ischemia/reperfusion – research on the preservation of cardiac function following a reduction in blood supply
Cardiomyocyte apoptosis —studies suggest a reduction in heart muscle cell death under ischemic conditions
Contractile Function —Measurement of Cardiac Output and Ejection Fraction in Experimental Models

These cardioprotective effects represent a unique aspect of Hexareelin research that distinguishes it from other GHRP compounds. Results from preclinical studies suggest that the mechanism involves CD36-mediated signaling independent of circulating GH or IGF-1.
All of the above results are from preclinical studies (in vitro, isolated organs, animal models) and cannot be extrapolated to human use.

Research Note: Desensitization with Chronic Administration

Preclinical studies with hexarelin document the phenomenon of GHS-R1a receptor desensitization following repeated or chronic administration. This phenomenon—typical of receptor agonists—manifests as a gradual decrease in the amplitude of the GH response upon long-term exposure.
From a research perspective, this property is important when designing experimental protocols. Desensitization has been documented to varying degrees with other GHRP compounds as well, with hexarelin exhibiting this phenomenon to a greater extent than ipamorelin or GHRP-2.

Technical Specifications and Storage

Parameter	Value
Form	Freeze-dried powder
Quantity	5 mg per bottle
Purity	≥98% (HPLC verified)
CAS Number	140703-51-1
Molecular weight	887.0 Da
Sequence	His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂
Type	GHRP / GH secretagogue
Receptor	GHS-R1a (primary), CD36 (secondary)
Storage (long-term)	-20 °C (lyophilized)
Storage (after reconstruction)	2–8 °C, use within 28 days
Reconstitution	Bacteriostatic water or sterile water

Frequently Asked Questions About Hexarelin

1. What distinguishes Hexarelin from other GHRP peptides, such as GHRP-2 or Ipamorelin?

Hexarelin differs from other GHRP compounds in two main ways: (1) greater GH-stimulating potency in preclinical models and (2) a unique cardioprotective mechanism via the CD36 receptor that is independent of GH secretion—this effect has not been documented for GHRP-2 or ipamorelin.

2. What is the GHS-R1a receptor, and why is it important in Hexarelin research?

GHS-R1a (Growth Hormone Secretagogue Receptor 1a) is a ghrelin receptor expressed on somatotrophic cells of the pituitary gland. Its activation by hexarelin triggers the release of endogenous GH. This receptor is a key target for the entire class of GHRP compounds.

3. What is the cardioprotective effect of Hexarelin, and how is it related to CD36?

CD36 is a scavenger receptor present on cardiomyocytes. Preclinical studies show that Hexarelin binds to it, thereby mediating cardioprotective effects (reduced apoptosis during ischemia) independently of systemic GH secretion. This property is unique within the GHRP class, as demonstrated by research.

4. What is GHS-R1a desensitization, and how does it affect research protocols?

Desensitization refers to the gradual reduction in receptor response following chronic administration of agonists. With hexarelin, this phenomenon has been documented to a greater extent than with ipamorelin. Therefore, this aspect must be taken into account when designing research protocols involving repeated administration.

5. What is the purity of Hexarelin from jacked.sk?

Each batch achieves a purity of ≥98%, as verified by HPLC. A Certificate of Analysis (COA) is available upon request.

6. How is Hexarelin reconstituted for research use?

Reconstitute the freeze-dried powder with bacteriostatic or sterile water. Use the dosage calculator at jacked.sk. Store the reconstituted solution at 2–8 °C and use within 28 days.

Notice – Intended exclusively for research purposes

All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, cosmetic product, or for human or veterinary use. The results stated in the product descriptions are based on preclinical studies (in vitro, animal models, isolated organs) and cannot be automatically extrapolated to human use. Sales are limited to individuals over the age of 18.

All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models, isolated organs) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18.

⚠️ Warning – Intended exclusively for research purposes

All products sold on jacked.sk are intended EXCLUSIVELY for scientific research purposes. They are not intended for use as a medicine, drug, dietary supplement, or cosmetic product, nor for human or veterinary use. The results cited in the descriptions are based on preclinical studies (in vitro, animal models) and cannot be automatically extrapolated to human use. Sale restricted to individuals over the age of 18. By purchasing this product, the customer confirms that they are a professional researcher and will use the product solely in accordance with applicable laws.